Skip to main content
Premium Trial:

Request an Annual Quote

Dionex Closes ESA Biosciences' HPLC Assets Buy

NEW YORK (GenomeWeb News) - Dionex said today that it has closed its purchase of HPLC products, clinical assays, and lab services from ESA Biosciences' parent company, Magellan Biosciences, in a deal that was struck in mid-September.

Under the deal, Sunnyvale, Calif.-based Dionex will gain three lines of HPLC detectors. These products include the Corona Universal Charged Aerosol Detectors, which Dionex will sell with its own HPLC equipment or directly on third party systems. The other two product lines, the CoulArray and Coulocheme electrochemical detectors are targeted at clinical, metabolomics, and neuroscience applications.

Financial terms of the agreement were not released.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.